Relevant bibliographies by topics / Abstract Targeted radionuclide therapy (TRT)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Abstract Targeted radionuclide therapy (TRT)'

Author: Grafiati
Published: 6 July 2024
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Abstract Targeted radionuclide therapy (TRT).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Abstract Targeted radionuclide therapy (TRT)"

1

Nguyen, Thanh Phuong T., Caroline P. Kerr, Joseph J. Grudzinski, et al. "Abstract 6407: Radionuclide-specific effects of90Y-,177Lu-, or225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhanced immunotherapy response in syngeneic murine tumors." Cancer Research 83, no. 7_Supplement (2023): 6407. http://dx.doi.org/10.1158/1538-7445.am2023-6407.

Full text
Abstract:
Abstract Background: Targeted radionuclide therapy (TRT) delivers radiation treatment systemically to tumor sites via a therapeutic radionuclide-linked tumor-selective targeting vector. NM600 is an alkylphosphocholine analog selectively taken up and retained in murine and human tumor cells. We previously showed that low dose radiation delivery with 90Y-NM600 improves tumor response to immune checkpoint inhibitors (ICIs). Understanding the effect of different radionuclide physical properties (emission type, linear energy transfer (LET), half-life, and tissue range) on immunomodulation of metast
APA, Harvard, Vancouver, ISO, and other styles
2

Kerr, Caroline P., Joseph J. Grudzinski, Carolina A. Ferreira, et al. "Abstract 2828: Impact of sequencing of immune checkpoint blockade and targeted radionuclide therapy on murine tumor response." Cancer Research 83, no. 7_Supplement (2023): 2828. http://dx.doi.org/10.1158/1538-7445.am2023-2828.

Full text
Abstract:
Abstract Background: Sequencing of immune checkpoint inhibitors (ICI) and external beam radiation therapy (EBRT) for cancer treatment has been studied, but the optimal sequencing has yet to be determined. While some studies have noted therapeutic advantages of priming the tumor immune microenvironment with EBRT prior to ICI, others have described the benefit of modulating the tumor infiltrating lymphocyte (TIL) population with ICI before EBRT. Targeted radionuclide therapy (TRT) approaches allow investigation of how irradiation by a tumor-targeted radionuclide and differences in emission type,
APA, Harvard, Vancouver, ISO, and other styles
3

Pal, Debjani, Miguel Toro Gonzáleza, Amber N. Bibleb, et al. "Abstract 480: Nanotherapeutic strategies to improve targeted radionuclide therapy." Cancer Research 84, no. 6_Supplement (2024): 480. http://dx.doi.org/10.1158/1538-7445.am2024-480.

Full text
Abstract:
Abstract Cancer is a leading cause of death worldwide. Several multidisciplinary approaches exist for cancer treatment, including radiotherapy and chemotherapy. Radiotherapy uses high-energy radiation to kill cancer cells; chemotherapy inhibits cancer cell proliferation and often kills cells by targeting the cell cycle. Resistance to radiotherapy and chemotherapy is a key determining factor in the outcome of therapeutic efficacy. Conventional nontargeted radiotherapy also affects distant nonirradiated cells, leading to DNA damage and changes in the cell cycle that are often linked to secondary
APA, Harvard, Vancouver, ISO, and other styles
4

Adhikarla, Vikram, Dennis Awuah, Alexander B. Brummer, et al. "Abstract 2732: A mathematical model for optimization of combination therapy involving targeted radionuclide and CAR-T cell therapy." Cancer Research 82, no. 12_Supplement (2022): 2732. http://dx.doi.org/10.1158/1538-7445.am2022-2732.

Full text
Abstract:
Abstract Background: Immunotherapy with chimeric antigen receptor - T (CAR-T) cells and targeted radionuclide therapy (TRT) are two highly promising therapies in cancer treatment. Often, these therapies show limited efficacy in complete eradication of cancer cells making the combination of these two therapies an attractive cancer treatment option. The complications involved in dosing and scheduling of these therapies make mathematical modeling an appropriate method for analyzing and predicting disease response to these therapies. Here we propose a mathematical model evaluating disease response
APA, Harvard, Vancouver, ISO, and other styles
5

Kerr, Caroline P., Amber M. Bates, Joseph J. Grudzinski, et al. "Abstract 1306: Radionuclide-specific effects of 90Y-, 177Lu-, or 225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhancing immunotherapy response in murine tumor models." Cancer Research 82, no. 12_Supplement (2022): 1306. http://dx.doi.org/10.1158/1538-7445.am2022-1306.

Full text
Abstract:
Abstract Purpose: In preclinical studies, we have demonstrated that delivering low dose radiation to all tumor sites utilizing 90Y-NM600 improves the response to immune checkpoint inhibitors (ICIs). NM600 is an alkylphosphocholine analog that is selectively taken up and retained in murine and human tumors. In this study, the immunomodulatory capacities of three distinct radionuclides (90Y, 177Lu, 225Ac) were compared using immunologically cold syngeneic murine tumor models: MOC2 head and neck squamous cell carcinoma (HNSCC) and B78 melanoma. We hypothesized that physical properties of radionuc
APA, Harvard, Vancouver, ISO, and other styles
6

Adhikarla, Vikram, Dennis Awuah, Enrico Caserta, et al. "Abstract 7374: Mathematical modeling of targeted radionuclide therapy and CAR-T cell immunotherapy for maximizing therapeutic efficacy in multiple myeloma." Cancer Research 84, no. 6_Supplement (2024): 7374. http://dx.doi.org/10.1158/1538-7445.am2024-7374.

Full text
Abstract:
Abstract Background: Resistance of cancer cells to monotherapies has led to the development of sequential or combination therapy regimens. However, dosing and scheduling of these therapies is challenging due to the numerous dosing and scheduling combinations that can be given. Mathematical models are thus critical tools for addressing this challenge as multiple therapy combinations can be tested in silico to finalize a patient-specific therapeutic regimen in vivo. Here we develop a mathematical framework for combining targeted radiation therapy (TRT) with Chimeric Antigen Receptor (CAR)-T cell
APA, Harvard, Vancouver, ISO, and other styles
7

Ruder, Samuel, Michael Sun, Andres Ricaurte Fajardo, et al. "Abstract 7582: Descriptive analysis of patients with mCRPC and liver metastases receiving alpha and beta PSMA targeted radionuclide therapy (PSMA-TRT)." Cancer Research 84, no. 6_Supplement (2024): 7582. http://dx.doi.org/10.1158/1538-7445.am2024-7582.

Full text
Abstract:
Abstract Introduction: Predictors of outcomes after PSMA-TRT are still being established. Liver metastases (mets) have been associated with poor response. Mutations in genes encoding DNA damage repair (DDR) and TP53 affect radiosensitivity. Here we describe a cohort of patients with mCRPC and liver metastases treated on clinical trials of PSMA-TRT. Methods: 39 patients with liver mets were enrolled on phase I/II PSMA-TRT studies between Jan 2006 to Apr 2022. Patients received alpha therapy (225Ac-J591), beta therapy (fractionated 177Lu-PSMA-617, single-dose and fractionated 177Lu-J591) or a co
APA, Harvard, Vancouver, ISO, and other styles
8

Sheehan-Klenk, Julia, Caroline P. Kerr, Thanh P. Nguyen, et al. "Abstract 6117: Dose, dose rate, and linear energy transfer influence tumor immunologic and DNA damage response following alpha- and beta-emitting radionuclides." Cancer Research 83, no. 7_Supplement (2023): 6117. http://dx.doi.org/10.1158/1538-7445.am2023-6117.

Full text
Abstract:
Abstract Background: The low response rate to immunotherapies in poorly immunogenic cancers highlights the potential for combination therapies that propagate an anti-tumor response in metastatic settings. Targeted radionuclide therapy (TRT) can deliver radiation to metastatic tumor sites. In preclinical studies, combining low dose TRT with immune checkpoint blockade augments the anti-tumor immune response, promoting the immune susceptibility of metastatic disease sites. Radionuclides differ in their physical properties such as emission type, linear energy transfer (LET), half-life, and tissue
APA, Harvard, Vancouver, ISO, and other styles
9

Garcia-Prada, Clara Diaz, Lena Carmes, Ali Parach, et al. "Abstract P009: Gadolinium-based nanoparticles sensitize ovarian peritoneal carcinomatosis to targeted radionuclide therapy." Clinical Cancer Research 31, no. 2_Supplement (2025): P009. https://doi.org/10.1158/1557-3265.targetedtherap-p009.

Full text
Abstract:
Abstract In 2024, around 13,000 women are expected to die from Ovarian Cancer (OC) in the US. Masked disease progression leads to late-stage diagnosis after the disease has spread to the peritoneal cavity (peritoneal carcinomatosis, PC). Treatments do not show substantial curative benefits, as disease will reoccur in 70-90% of patients. Targeted Radionuclide Therapy (TRT) specifically irradiates tumors sparing the surrounding healthy tissues, offering an attractive therapeutic option for metastatic spread. Here, we investigated the radiosensitizing effects of Gadolinium-based nanoparticles (Gd
APA, Harvard, Vancouver, ISO, and other styles
10

Cold, Sigrid, Pragalath Sadasivam, Myrto Ischyropoulou, et al. "Abstract 570: Preclinical insights into 161Tb-trastuzumab and immune checkpoint combination therapy for cancer in a HER2-expressing murine cancer model." Cancer Research 85, no. 8_Supplement_1 (2025): 570. https://doi.org/10.1158/1538-7445.am2025-570.

Full text
Abstract:
Abstract Introduction: Targeted radionuclide therapy (TRT) is a unique treatment option allowing for in vivo imaging and delivery of lethal radiation directly and specifically to solid cancers. As TRT is generally well-tolerated with limited side effects, it holds a significant potential for use in combination with other therapies such as immunotherapy. However, preclinical assessment of this combinational pair has been limited by the lack of relevant animal models. To address this, we established a fully immunocompetent animal model bearing murine tumors expressing a human target making the m
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Abstract Targeted radionuclide therapy (TRT)"

1

Rouanet, Jacques. "Radiothérapie interne du mélanome métastatique pigmenté : mécanismes et associations." Electronic Thesis or Diss., Université Clermont Auvergne‎ (2017-2020), 2019. http://www.theses.fr/2019CLFAS033.

Full text
Abstract:
La radiothérapie interne vectorisée ou RIV consiste à adresser spécifiquement un isotope radioactif aux tumeurs grâce à un vecteur spécifique. Dans le cas du mélanome, le vecteur utilisé pour la RIV peut être un anticorps ciblant des antigènes de surface ou la mélanine, des analogues peptidiques capables de se fixer sur des récepteurs tumoraux (comme le récepteur à la melanocyte-stimulating hormone) ou des petites molécules se liant à la mélanine (dérivées des benzamides). Ainsi, notre équipe travaille sur cette dernière stratégie depuis 15 avec la molécule phare [ 131 I]ICF01012. De nombreuse
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Abstract Targeted radionuclide therapy (TRT)"

1

Koniar, Helena, and Paul Schaffer. "Alpha-particle Emitting Radiopharmaceuticals in Targeted Therapy and Diagnostics: Challenges and Opportunities." In Targeted Radiopharmaceuticals and Imaging. Royal Society of Chemistry, 2025. https://doi.org/10.1039/9781837677139-00056.

Full text
Abstract:
Targeted Radionuclide Therapy (TRT) demonstrates significant therapeutic efficacy and survival benefits, especially for late-stage metastatic cancers with limited conventional therapy options. The majority of TRT radiopharmaceuticals rely on beta-emitting radionuclides, but more recently the global radiopharmaceutical community has come to appreciate the advantages of alpha-emitting radionuclides. Targeted alpha therapy (TAT) is now a fast-growing area of TRT, focused on the identification, development, and translation of alpha-emitting radiopharmaceuticals, several of which have started to sh
APA, Harvard, Vancouver, ISO, and other styles
2

"Monoclonal antibody targeted radionuclide therapy." In Targeted Therapy for Cancer, edited by Surinder K. Batra, Apollina Goet Gabriela Pavlinkova, and David Colcher. Oxford University PressOxford, 2003. http://dx.doi.org/10.1093/oso/9780198508960.003.0005.

Full text
Abstract:
Abstract The pivotal work by Kohler and Milstein (1) on the development of hybridoma technology has made the production of an unlimited supply of monoclonial antibody (mAb) molecules possible. A wide range of mAbs has been generated for applications in research and health care. mAbs have made an impact in clinical medicine for the treatment of cancer, infectious diseases, and the immunomodulation of transplant rejection.
APA, Harvard, Vancouver, ISO, and other styles
3

Sharma, Vipasha, Suman Khurana, Mukesh Rani, Arun Mittal, and Parveen Kumar Goyal. "RADIOPHARMACEUTICALS." In Futuristic Trends in Pharmacy & Nursing Volume 3 Book 20. Iterative International Publisher, Selfypage Developers Pvt Ltd, 2024. http://dx.doi.org/10.58532/v3bgpn20p2ch3.

Full text
Abstract:
Radiopharmaceuticals (RPs) have revolutionized the fields of nuclear medicine, diagnostic imaging, and targeted therapy. The chapter begins by elucidating the brief explanation of production and design of RPs. This chapter focuses on newly produced diagnostic & therapeutic radiopharmaceuticals that are being employed in normal clinical settings as well as innovative, exciting technologies and agents for the treatment of cancer and other chronic diseases. In this chapter, we delve into the introduction and key applications of therapeutic RPs, with a focus on radio immunotherapy (RIT) and ta
APA, Harvard, Vancouver, ISO, and other styles
4

Bhandare, Manish S., Vikas Gupta, Vikram A. Chaudhari, and Shailesh V. Shrikhande. "Neuroendocrine Tumours of the Pancreas." In Pancreas, edited by Shailesh V. Shrikhande, Markus W. Büchler, Samiran Nundy, and Dirk J. Gouma. Oxford University PressOxford, 2022. http://dx.doi.org/10.1093/med/9780192858443.003.0011.

Full text
Abstract:
Abstract Most pancreatic neuroendocrine tumours (p-NETs) have a sporadic occurrence and less than 10% form a part of various familial syndromes. Broadly, they can be classified as functional and non-functional tumours, based on the presence or absence of hormone secretion. Biological aggressiveness of p-NETs is determined by their degree of differentiation and rate of proliferation, and they are graded as per the World Health Organization’s classification into three grades (G1, G2, and G3). For evaluation and accurate staging of p-NETs, functional imaging has become an integral part of work-up
APA, Harvard, Vancouver, ISO, and other styles
5

Bharati, Dr Deepak, Prajwal Bari, Sakshi Nirhali, Jishaan Alam Khan, and Pratiksha Umale. "RADIOPHARMACEUTICAL SCIENCE." In Futuristic Trends in Pharmacy & Nursing Volume 3 Book 12. Iterative International Publisher, Selfypage Developers Pvt Ltd, 2024. http://dx.doi.org/10.58532/v3bgpn12p5ch4.

Full text
Abstract:
Radiopharmaceutical science is a multidisciplinary field that plays a pivotal role in nuclear medicine, utilizing radiopharmaceutical agents for diagnostic imaging, therapeutic applications, and molecular target-specific therapy. This abstract provides an overview of the key aspects and advancements in radiopharmaceutical science. In the realm of diagnostic imaging, radiopharmaceuticals are employed to visualize and assess physiological and pathological processes at the molecular level. Techniques such as Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET)
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Abstract Targeted radionuclide therapy (TRT)"

1

Gill, Martin R., Jyothi U. Menon, Robert Carlisle, and Katherine A. Vallis. "Abstract 994: Combining ruthenium metallo-intercalators and targeted radionuclide therapy for EGFR-overexpressing oesophageal cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-994.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gill, Martin R., Jyothi U. Menon, Robert Carlisle, and Katherine A. Vallis. "Abstract 994: Combining ruthenium metallo-intercalators and targeted radionuclide therapy for EGFR-overexpressing oesophageal cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-994.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jensen, Mette Munk, Jesper Fonslet, Camilla S. Knudsen, et al. "Abstract 5203: Tissue factor targeted radionuclide therapy with177Lu-FVIIai inhibits tumor growth of human pancreatic cancer xenografts." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-5203.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jagodinsky, Justin C., Ian S. Arthur, Juliana S. Castillo, et al. "Abstract 477: Comparing type 1 interferon activation in tumor cells following external beam radiotherapy versus targeted radionuclide therapy." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-477.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sun, Michael, Muhammad Niaz, Charlene Thomas, et al. "Abstract 6511: Androgen receptor (AR) genomic alterations and clinical outcome with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-6511.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jagodinsky, Justin C., Amber M. Bates, Reinier Hernandez, et al. "Abstract 3060: Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-3060.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Potluri, Hemanth Kumar, Reinier Hernandez, Christopher D. Zahm, et al. "Abstract 2262: Low-dose targeted radionuclide therapy has favorable local and systemic effects on immune populations in a murine prostate cancer model." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-2262.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sosa, Gustavo A., Amber M. Bates, Ravi Patel, et al. "Abstract 903:In vivoefficacy of bempegaldesleukin, immune checkpoint inhibition, and targeted radionuclide therapy in immunocompetent murine model of head and neck cancer." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-903.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kwan, Tanya T., Minh Nguyen, Dirk Zboralski, et al. "Abstract LBA032: Pan-cancer analysis of fibroblast activation protein alpha (FAP) expression to guide tumor selection for the peptide-targeted radionuclide therapy FAP-2286." In Abstracts: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; October 7-10, 2021. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1535-7163.targ-21-lba032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Emma, Sarah E., Amber M. Bates, Reinier Hernandez, et al. "Abstract 508: Mechanisms of cooperative response to bempegaldesleukin (BEMPEG) and90Y-NM600 targeted radionuclide therapy in the treatment of a syngeneic murine model of head and neck squamous cell carcinoma." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-508.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Abstract Targeted radionuclide therapy (TRT)' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography